CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
This article was originally published in The Tan Sheet
Executive Summary
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.
You may also be interested in...
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry
ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
The Electronic Retailing Self-Regulation Program referred advertising for NVE Pharmaceuticals' AppuLoss dietary supplement to the Federal Trade Commission after the firm failed to respond to an inquiry